Konsume
Interval Day Week Month
Newswire Search Past 90 Days 347 stories 52 Publishers
Trending Today
Sort By: Snapshot
Buzz
Media Coverage
World View

Related Topics
Topic # Mentions Topic Reach
phase40-
the28-
data27-
biotech24-
study21-
ipo11-
summit10-
develop8-
lilly8-
rna8-
collaboration7-
research7-
next6-
nda6-
medical6-
ind6-
sign5-
pharma5-
positive5-
viking5-
oncology5-
launches5-
concerns5-
financing4-
center4-
partnership4-
pipeline4-
adc4-
startup4-
firm4-
placement3-
runway3-
blood3-
public offering3-
stock rises3-
share3-
theft3-
ivonescimab3-
response3-
shares fall3-
fall3-
strong3-
Prominent Journalists
Byline Articles Written Avg Reach
RTTNews Staff Writer 129 -
By Salong Debbarma 25 -
by PR Newswire 18 -
Frank Vinluan 17 -
Gayathry Prakash 15 -
Prabha Kurup 14 -
TajSabreen Ahamed 11 -
Bob D'Angelo, Cox Media Group National Content Desk 5 -
Adam Feuerstein 4 -
Elaine Chen 3 -
Lori DeBoer 3 -
Tony Jackson 3 -
Jason Mast 3 -
PBN Staff 2 -
Thomas Hughes 2 -
Murray Ward 2 -
Meghana Keshavan 2 -
By srivani venna 2 -
Lucas High 2 -
Mica Kanner-Mascolo 2 -


Viking Therapeutics Q3 2026 Earnings Date and Estimates

October 27 at 3:13 AM  |  americanbankingnews.com — marketbeat.com


Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down

TajSabreen Ahamed — rttnews.com


3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

Bridget Bennett — marketbeat.com


Patient CRM Modernization: Four Decisions Technology Can't Make for You

HITC Staff — hitconsultant.net


Aclaris Therapeutics Shares Fall 3% After Announcement Of ATI-052 Study Data, Stock Offering Pricing

RTTNews Staff Writer — rttnews.com


PYC Therapeutics Shares Surge 9.4% as RNA Drug Developer Rebounds After Pullback Following Kidney Disease Data

Tony Jackson — ibtimes.com.au


Lycia Shares Fall Nearly 10% After Hours Following $365.1 Mln IPO Closing

RTTNews Staff Writer — rttnews.com


Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

Bridget Bennett — marketbeat.com


Can-Fite Presents Final Phase 2a Data For Namodenoson In Pancreatic Cancer

Gayathry Prakash — rttnews.com


Oruka Therapeutics Stock Jumps 12% After Positive Phase 2b Psoriasis Trial

RTTNews Staff Writer — rttnews.com

Execution: 2.08 Seconds. 33.81 mb used.